Nuclear bcl-2 Staining in Tumors

Immunohistochemical nuclear staining for p53, PCNA, Ki-67 and bcl-2 in different histologic variants of basal cell carcinoma.

BACKGROUND Basal cell carcinoma is the most common form of human cancer. Increased expression of p53 has been found in the majority of basal cell carcinomas (BCCs); however, UV-light-induced signature mutations are present in only about 50% of cases. Increased nuclear staining with an immunohistochemical marker of proliferation and apoptosis has been correlated with aggressive behavior in BCC. ...

bcl-2, Epstein-Barr virus-latent membrane protein, EBNA-1, and EBNA-2 staining in posttransplantation lymphoproliferative disorders.

We read with great interest the report by Murray et al.' We have analyzed 3 1 posttransplantation lymphoproliferative disorders (PTLDs; 18 renal and 13 heartheart-lung cases) for bcl-2, EpsteinBarr virus-latent membrane protein (EBV-LMP), EBNA-l, and EBNA-2.2.5 We used the same antibodies as Murray et al.' All cases were EBV-LMP-l -positive. In more than 90% of cases, 80% of the neoplastic popu...

Evaluation of Bcl-2, Bcl-x and cleaved caspase-3 in malignant peripheral nerve sheath tumors and neurofibromas.

AIMS To study the expression of Bcl-2, Bcl-x, as well the presence of cleaved caspase-3 in neurofibromas and malignant peripheral nerve sheath tumors. The expression of Bcl-2 and Bcl-x and the presence of cleaved caspase 3 were compared to clinicopathological features of malignant peripheral nerve sheath tumors and their impact on survival rates were also investigated. MATERIALS AND METHODS T...

Bcl-2

Recent findings from our laboratory provide the first indication that overexpression of Bcl-2 in Eµ-myc transgenic cells enhances tumor immunosurveillance by inducing NKG2D ligands. Initial evidence suggests that this model is relevant to human patients. Thus, antitumor therapies that target Bcl-2 harbor the risk of reducing tumor immunogenicity.

Non-nuclear staining of thick tissue sections.